6291-10-7

Basic information

• Product Name: 4-Pyridinecarboxylic acid, 2-chloro-6-ethoxy-
• Synonyms: 4-Pyridinecarboxylic acid, 2-chloro-6-ethoxy-;2-CHLORO-6-ETHOXYISONICOTINIC ACID
• CAS NO: 6291-10-7
• Molecular Formula: C₈H₈ClNO₃
• Molecular Weight: 201.60702
• Mol File: 6291-10-7.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 409.7°C at 760 mmHg
• Flash Point: 201.6°C
• Appearance: /
• Density: 1.365g/cm³
• Vapor Pressure: 1.9E-07mmHg at 25°C
• Refractive Index: 1.556
• CAS DataBase Reference: 4-Pyridinecarboxylic acid, 2-chloro-6-ethoxy-(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Pyridinecarboxylic acid, 2-chloro-6-ethoxy-(6291-10-7)
• EPA Substance Registry System: 4-Pyridinecarboxylic acid, 2-chloro-6-ethoxy-(6291-10-7)

Safety Data

• Hazardous Substances Data: 6291-10-7(Hazardous Substances Data)

Usage

General Description

The chemical 4-Pyridinecarboxylic acid, 2-chloro-6-ethoxy- is a compound with the molecular formula C8H8ClNO3. It is a derivative of pyridinecarboxylic acid, containing a chloro and an ethoxy functional group at specific positions in the molecular structure. 4-Pyridinecarboxylic acid, 2-chloro-6-ethoxy- is commonly used in the pharmaceutical industry for the synthesis of various drugs and pharmaceutical products. It may also have applications in organic synthesis and chemical research. The specific properties and potential uses of 4-Pyridinecarboxylic acid, 2-chloro-6-ethoxy- may vary depending on the specific context and application.

InChI:InChI=1/C8H8ClNO3/c1-2-13-7-4-5(8(11)12)3-6(9)10-7/h3-4H,2H2,1H3,(H,11,12)

Upstream product

• 141-52-6 sodium ethanolate 
• 5398-44-7 2,6-dichloropyridine-4-carboxylic acid 
• 64-17-5 ethanol 

Downstream Products

• 1370448-69-3 2-(4-(tert-butoxycarbonyl)phenyl)-6-ethoxyisonicotinic acid 
• 91940-86-2 2-ethoxyisonicotinic acid 

Relevant articles and documents

Design, synthesis and biological evaluation of sphingosine-1-phosphate receptor 2 antagonists as potent 5-FU-resistance reversal agents for the treatment of colorectal cancer

5-Fluorouracil (5-FU) and its prodrugs are the essential clinical drugs for colorectal cancer (CRC) treatment. However, the drug resistance of 5-FU has caused high mortality of CRC patients. Thus, it is urgent to develop reversal agents of 5-FU resistance. Sphingosine-1-phosphate receptor 2 (S1PR2) was proved to be a potential target for reversing 5-FU resistance, but the activity of known S1PR2 antagonists JTE-013 were weak in 5-FU-resistant cell lines. To develop more potent S1PR2 antagonists to treat 5-FU-resistant cancer, a series of JTE-013 derivatives were designed and synthesized. The most promising compound 40 could markedly reverse the resistance in 5-FU-resistant HCT116 cells and 5-FU-resistant SW620 cells via inhibiting the expression of dihydropyrimidine dehydrogenase (DPD). The key was that compound 40 with improved pharmacokinetic properties significantly increased the inhibitory rate of 5-FU in the SW620/5-FU cells xenograft model with no observable toxicity by inhibiting the expression of DPD in tumor and liver tissues. Altogether, these results suggest that compound 40 may be a promising drug candidate to reverse 5-FU resistance in the treatment of CRC.